Sage Journals: Discover world-class research

Abstract

Background: It has been reported that omeprazole is mainly metabolized via the hepatic cytochrome (CYP) 1A1/2, 3A1/2, and 2D1, and the expressions and mRNA levels of CYP1A2, 2C11, and 3A1/2 decreased in protein-calorie malnutrition (PCM) rats compared with controls. Interestingly, the decreased CYP1A2, 2C11, and 3A1/2 in PCM rats returned fully or partially to control levels by oral cysteine supplementation (PCMC rats). Hence, it could be expected that some pharmacokinetic parameters of omeprazole might change in PCM rats and partially restore to control levels in PCMC rats. The purpose of this study is to investigate the pharmacokinetic changes of omeprazole in PCM rats and restoration of the parameters in PCMC rats to control levels. Methods: Omeprazole was administered intravenously (20 mg/kg) and orally (40 mg/kg) to control, PCM, and PCMC rats. Results: The following pharmacokinetic parameters were changed in PCM rats and partially returned to control levels in PCMC rats: the area under the plasma concentration-time curve (AUC; 387, 762, and 539 μg min/mL for control, PCM, and PCMC rats, respectively, after intravenous [IV] administration, and the corresponding values after oral administration: 115, 304, and 201 μg min/mL), total body clearance (51.7, 25.5, and 37.1 mL/min/kg, respectively), nonrenal clearance (51.5, 25.4, and 36.1 mL/min/kg, respectively), and in vitro intrinsic clearance (0.158, 0.118, and 0.138 mL/min/mg protein). Conclusions: PCM was associated with significant changes in some omeprazole pharmacokinetics and the pharmacokinetic parameters restored to control levels by oral cysteine.

Pharmacokinetic parameters of omeprazole were evaluated in control, cysteine control, protein-calorie malnutrition (PCM), and PCMC rats. Partial restoration of some parameters (such as area under the plasma concentration-time curve, total body clearance, and nonrenal clearance) in PCM rats by oral cysteine supplementation (PCMC rats) to control levels was expected according to restoration of hepatic cytochrome (CYP) 1A2, 2C11, and 3A1/2 in PCMC rats to control levels.

Get full access to this article

View all access options for this article.

References

Denke M, Wilson JD. Protein and energy malnutrition. In: Fauci AS, Braunwald E, Isselbacher KJ, et al, eds. Principles of Internal Medicine. 14^th ed. New York, NY: McGraw-Hill;1998 : 452–454.

Buchanan N. Drug kinetics in protein energy malnutrition. S Afr Med J. 1978;53:327– 330.

Krishnaswamy K. Drug metabolism and pharmacokinetics in malnutrition. Clin Pharmacokinet. 1978 ;3:216– 240.

Lee JH, Suh OK, Lee MG. Pharmacokinetic changes in drugs during protein-calorie malnutrition: correlation between drug metabolism and hepatic microsomal cytochrome P450 isozymes. Arch Pharm Res. 2004 ;27:693– 712.

Cho MK, Kim YG, Lee MG, Kim SG. Suppression of rat hepatic cytochrome P450s by protein-calorie malnutrition: complete or partial restoration by cysteine or methionine supplementation. Arch Biochem Biophys. 1999;372:150– 158.

Im W, Blakeman DP, Davis JP. Irreversible inactivation of rat gastric (H⁺-K⁺)-ATPase in vivo by omeprazole.Biochem Biophys Res Commun. 1985 ;126:78– 82.

Lee DY, Shin HS, Bae SK, Lee MG. Effects of enzyme inducers and inhibitors on the pharmacokinetics of intravenous omeprazole in rats.Biopharm Drug Dispos. 2006 ;27:209– 218.

Paula AC, Gracioso JS, Toma W, et al. Is gastric ulceration different in normal and malnourished rats? Br J Nutr. 2005 ;93:47– 52.

Kawai T, Teshima S, Kusumoto K, et al. A non-toxic heat shock protein 70 inducer, geranyl-geranyl-acetone, restores the heat shock response in gastric mucosa of protein-malnourished rats. J Lab Clin Med. 2000 ;136:138– 148.

10.

Sezer S, Ibis A, Ozdemir BH, et al. Association of Helicobacter pylori infection with nutritional status in hemodialysis patients.Transplant Proc. 2004;36:47– 49.

11.

Borras-Blasco J, Navarro-Ruiz A, Navarro-Blasco F, Tovar-Beltran J, Gonzalez-Delgado M. Erythrodermia induced by omeprazole. Int J Clin Pharmacol Ther. 2001;39:219– 223.

12.

Lutz M, Schwab M, Griese EU, et al. Visual disorders associated with omeprazole and their relation to CYP2C19 polymorphism.Pharmacogenetics. 2002;12:73– 75.

13.

Bae SK, Yang SH, Kim JW, Kim T, Kwon JW, Lee MG. Effects of cysteine on the pharmacokinetics of oltipraz in rats with protein-calorie malnutrition. J Pharm Sci. 2005 ;94:1484– 1493.

14.

Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976 ;72:248– 254.

15.

Kang WK, Kim DS, Kwon KI. Advanced method for determination of omeprazole in plasma by HPLC. Arch Pharm Res. 1999 ;22:86– 88.

16.

Duggleby RG. Analysis of enzyme progress curves by nonlinear regression. Methods Enzymol. 1995 ;249:61– 90.

17.

Shim HJ, Lee EJ, Kim SH, et al. Factors influencing the protein binding of a new phosphodiesterase V inhibitor, DA-8159, using an equilibrium dialysis technique. Biopharm Drug Dispos. 2000 ;21:285– 291.

18.

Kim SH, Choi YM, Lee MG. Pharmacokinetics and pharmacodynamics of furosemide in protein-calorie malnutrition. J Pharmacokinet Biopharm. 1993;21:1– 17.

19.

Watanabe K, Matsuka N, Okazaki M, Hashimoto Y, Araki H, Gomita Y. The effect of immobilization stress on the pharmacokinetics of omeprazole in rats. Acta Med Okayama. 2002 ;56:19– 23.

20.

Chiou WL. Critical evaluation of potential error in pharmacokinetic studies using the linear trapezoidal rule method for the calculation of the area under the plasma level-time curve. J Pharmacokinet Biopharm. 1978;6:539– 549.

21.

Gibaldi M, Perrier D. Pharmacokinetics. 2^nd ed. New York, NY: Marcel-Dekker, Inc;1982 .

22.

Chiou WL. New calculation method of mean apparent drug volume of distribution and application to rational dosage regimen. J Pharm Sci. 1979;68:1067– 1069.

23.

Eatman FB, Colburn WA, Boxenbaum HG, et al. Pharmacokinetics of diazepam following multiple dose oral administration to healthy human subjects. J Pharmacokinet Biopharm. 1977 ;5:481– 494.

24.

Chiou WL. New calculation method of mean total body clearance of drugs and its application to rational dosage regimens. J Pharm Sci. 1980;69:90– 91.

25.

Mitruka BM, Rawnsley HM. Clinical, Biochemical and Hematological Reference Values in Normal Experimental Animals and Normal Humans. 2^nd ed. New York, NY: Masson Publishing Inc;1981 : 163.

26.

Obama M, Cangir A, van Eys J. Nutritional status and anthracycline cardiotoxicity in children. South Med J.1983 ;76:577– 578.

27.

Gamelli RL, Foster RS Jr. Effects of protein-calorie malnutrition and refeeding on fluorouracil toxicity. Arch Surg. 1983 ;118:1182– 1185.

28.

Brennan MF. Uncomplicated starvation versus cancer cachexia.Cancer Res. 1977;37:2359– 2364.

29.

Costa G. Cachexia, the metabolic component of neoplastic diseases.Cancer Res. 1977;37:2327– 2335.

30.

Watanabe K, Furuno K, Eto K, Oishi R, Gomita Y. First-pass metabolism of omeprazole in rats. J Pharm Sci. 1994 ;83:1131– 1134.

31.

Webster LK, Jones DB, Mihaly GW, Morgan DJ, Smallwood RA. Effect of hypoxia on oxidative and reductive pathways of omeprazole metabolism by the isolated perfused rat liver. Biochem Pharmacol. 1985 ;34:1239– 1245.

32.

Karam WG, Goldstein JA, Lasker JM, Ghanayem BI. Human CYP2C19 is a major omeprazole 5-hydroxylase, as demonstrated with recombinant cytochrome P450 enzymes. Drug Metab Dispos. 1996 ;24:1081– 1087.

33.

Wilkinson GR, Shand DG. A physiological approach to hepatic drug clearance. Clin Pharmacol Ther. 1975 ;18:377– 390.

34.

Remesy C, Demigne C. Changes in availability of glucogenic and ketogenic substrates and liver metabolism in fed or starved rats. Ann Nutr Metab. 1983;27:57– 70.

35.

Laperche Y, Preaux AM, Feldmann G, Mahu JL, Berthelot P. Effect of fasting on organic anion uptake by isolated rat liver cells.Hepatology. 1981;1:617– 621.

36.

Owen OE, Felig P, Morgan AP, Wahren J, Cahill GF Jr. Liver and kidney metabolism during prolonged starvation. J Clin Invest. 1969 ;48:574– 583.

37.

Zaramella MG, Vallini R, Tiribelli C. Estimation of the hepatic blood “flow” by galactose plasma clearance in patients with liver disease. Liver. 1985;5:129– 133.

38.

Khaled MA. Oxidative stress in childhood malnutrition and diarrhoeal diseases. J Diarrhoeal Dis Res. 1994 ;12:165– 172.

39.

Sodhi CP, Rana SF, Attri S, Mehta S, Yaiphei K, Mehta SK. Oxidative-hepatic injury of isoniazid-rifampicin in young rats subjected to protein and energy malnutrition. Drug Chem Toxicol. 1998 ;21:305– 317.

40.

Pahan K, Smith BT, Singh AK, Singh I. Cytochrome P-450 2E1 in rat liver peroxisomes: Downregulation by ischemia/reperfusion-induced oxidative stress. Free Radic Biol Med. 1997 ;23:963– 971.

41.

Stipanuk MH, Coloso RM, Garcia RA, Banks MF. Cysteine concentration regulates cysteine metabolism to glutathione, sulfate and taurine in rat hepatocytes. J Nutr. 1992 ;122:420– 427.

42.

Miura K, Ishii T, Sugita Y, et al. Cystine uptake and glutathione level in endothelial cells exposed to oxidative stress. Am J Physiol. 1992;262:C50– C58.

43.

Kim YG, Kim SK, Kwon JW, et al. Effects of cysteine on amino acid concentrations and transsulfuration enzyme activities in rat liver with protein-calorie malnutrition. Life Sci. 2003 ;72:1171– 1181.

44.

Kim YG, Cho MK, Kwon JW, Kim SG, Kim SH, Lee MG. Effects of cysteine on the pharmacokinetics and pharmacodynamics of intravenous and oral azosemide in rats with protein-calorie malnutrition. Life Sci. 2001 ;68:2329– 2345.

45.

Regardh CG, Gabrielsson M, Hoffman KJ, Lofberg I, Skanberg I. Pharmacokinetics and metabolism of omeprazole in animals and man: an overview.Scand J Gastroenterol. 1985 ;108(suppl):79– 94.

46.

Hakkak R, Ronis MJ, Badger TM. Effects of enteral nutrition and ethanol on cytochrome P450 distribution in small intestine of male rats.Gastroenterology. 1993;104:1611– 1618.

47.

Kaminsky LS, Fasco MJ. Small intestinal cytochromes P450.Crit Rev Toxicol. 1991;21:407– 422.

Effects of Cysteine on the Pharmacokinetic Parameters of Omeprazole in Rats With Protein-Calorie Malnutrition: Partial Restoration of Some Parameters to Control Levels by Oral Cysteine Supplementation

Abstract

Get full access to this article

References